Gunderson Thomas J.

SEC source: 0001193125-26-274178 · ownership.xml · derivative · entry 3

Gunderson Thomas J. · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,285 shares

Expires 2026-08-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock options were granted on August 1, 2016 and are fully vested.

SEC source: 0001193125-26-274178 · ownership.xml · nonDerivative · entry 2

Gunderson Thomas J. · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,642

F1 · kind: The shares were sold to cover the exercise price and applicable tax withholding obligations in connection with the exercise of the stock options.

SEC source: 0001193125-26-274178 · ownership.xml · nonDerivative · entry 1

Gunderson Thomas J. · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,266

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001708144-26-000004 · form4-05212026_010507.xml · derivative · entry 4

Gunderson Thomas J. · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires 2026-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001708144-26-000004 · form4-05212026_010507.xml · derivative · entry 3

Gunderson Thomas J. · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,750 shares

Expires 2026-05-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001708144-26-000004 · form4-05212026_010507.xml · nonDerivative · entry 2

Gunderson Thomas J. · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,741

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported transactions involved the reporting person's exercise of stock options for an aggregate of 21,250 shares of common stock. The exercise prices were paid in cash, and no shares were sold in connection with the option exercises.

SEC source: 0001708144-26-000004 · form4-05212026_010507.xml · nonDerivative · entry 1

Gunderson Thomas J. · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,241

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported transactions involved the reporting person's exercise of stock options for an aggregate of 21,250 shares of common stock. The exercise prices were paid in cash, and no shares were sold in connection with the option exercises.

SEC source: 0001193125-26-236912 · ownership.xml · nonDerivative · entry 1

Gunderson Thomas J. · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,981

F1 · shares: Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001708144-26-000002 · form4-05192026_100517.xml · nonDerivative · entry 1

Gunderson Thomas J. · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,491

F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 3,457 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan. The RSUs granted to the reporting person will vest on May 3, 2027. Vesting of the RSUs is subject to continued service to the issuer through the vesting date.

SEC source: 0000950170-25-077216 · ownership.xml · nonDerivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,059

F1 · shares: Consists of 2,134 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001415889-25-013724 · form4-05192025_100519.xml · nonDerivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,034

F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 2,152 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan. The RSUs vest on May 15, 2026. Vesting of the RSUs is subject to continued service to the issuer through the vesting date.

SEC source: 0001415889-25-006302 · form4-03042025_010348.xml · derivative · entry 3

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2025-06-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 06/07/2019.

SEC source: 0001415889-25-006302 · form4-03042025_010348.xml · nonDerivative · entry 2

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,882

F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.60 to $100.515, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-25-006302 · form4-03042025_010348.xml · nonDerivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,688

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-065399 · ownership.xml · derivative · entry 2

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,154

Underlying: Common Stock · 1,154 shares

Expires 2034-05-23

F2 · derivative.exercise_date: The option vests in full on the earlier of May 23, 2025 or the date of the 2025 annual meeting of the stockholders of the Issuer, subject to continued service.

SEC source: 0000950170-24-065399 · ownership.xml · nonDerivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,925

F1 · shares: Consists of 732 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001415889-24-013813 · form4-05202024_090509.xml · nonDerivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,688

F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 2,431 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan. The RSUs vest on May 16, 2025. Vesting of the RSUs is subject to continued service to the issuer through the vesting date.

SEC source: 0001415889-24-006503 · form4-03052024_050352.xml · derivative · entry 3

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2024-05-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 05/24/2018.

SEC source: 0001415889-24-006503 · form4-03052024_050352.xml · nonDerivative · entry 2

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,257

F1 · price: The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.00 to $76.25, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001415889-24-006503 · form4-03052024_050352.xml · nonDerivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-23-024880 · ownership.xml · derivative · entry 2

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,916

Underlying: Common Stock · 1,916 shares

Expires 2023-05-25

F2 · derivative.exercise_date: The option vests in full on the earlier of May 25, 2024 or the date of the 2024 annual meeting of the stockholders of the Issuer, subject to continued service.

SEC source: 0000950170-23-024880 · ownership.xml · nonDerivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,193

F1 · shares: Includes 1,193 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001415889-23-008481 · form4-05222023_060501.xml · nonDerivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,414

F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 2,262 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan. The RSUs vest on May 18, 2024. Vesting of the RSUs is subject to continued service to the issuer through the vesting date.

SEC source: 0000899243-22-021203 · doc4.xml · derivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2032-06-01

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant, June 1, 2023, or the date of the following annual meeting of shareholders of the Company.

SEC source: 0001415889-22-005730 · form4-05262022_030534.xml · nonDerivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,152

F1 · shares: The reported transaction involved the reporting person's receipt of a grant of 3,050 restricted stock units (RSUs) under the Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan. The RSUs vest on May 24, 2023. Vesting of the RSUs is subject to continued service to the issuer through the vesting date.

SEC source: 0001415889-21-003135 · form4-06212021_040655.xml · nonDerivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,102

F1 · balance_after: The reported transaction involved the reporting person's receipt of a grant of 2,914 restricted stock units under the Merit Medical System, Inc. 2018 Long-Term Incentive Plan. The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 of Table I includes the 2,914 newly awarded restricted stock units that vest on June 17, 2022 and 4,188 previously reported time-vesting restricted stock units that vest on June 22, 2021. Vesting of restricted stock units is subject to continued service to the issuer through the vesting date.

SEC source: 0000899243-21-021356 · doc4.xml · derivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2031-05-27

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant, May 27, 2022, or the date of the following annual meeting of shareholders of the Company.

SEC source: 0001415889-20-001704 · form4-06242020_050656.xml · derivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,188

Underlying: Common Stock · 4,188 shares

Expires 2021-06-22

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon vesting.

F2 · derivative.exercise_date: Each restricted stock unit vests on June 22, 2021 subject to continued service to the Issuer through the vesting date.

SEC source: 0000899243-20-015473 · doc4.xml · derivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,934

Underlying: Common Stock · 15,934 shares

Expires 2030-06-04

F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant, June 4, 2021, or the date of the following annual meeting of shareholders of the Company.

SEC source: 0000856982-19-000085 · wf-form4_155968073635572.xml · derivative · entry 4

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2026-05-31

F4 · derivative.exercise_date: Becomes exercisable in equal annual installments of 33% commencing 05/31/2020.

SEC source: 0000856982-19-000066 · wf-form4_155917124890156.xml · derivative · entry 3

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,750

Underlying: Common Stock · 13,750 shares

Expires 2026-05-24

F3 · derivative.exercise_date: Becomes exercisable in equal annual installments of 33% commencing 05/24/2020.

SEC source: 0000899243-19-012291 · doc4.xml · derivative · entry 2

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,285

Underlying: Common Stock · 19,285 shares

Expires 2026-08-01

F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F2 · derivative.exercise_date: The option will become exercisable as to 2.778% of the original number of shares at the end of each successive one-month period following the vesting commencement date, August 1, 2016, until the option is fully vested on the third anniversary of the vesting commencement date.

SEC source: 0000899243-19-012291 · doc4.xml · derivative · entry 1

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,285 shares

Expires 2026-08-01

F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated as of April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price.

F2 · derivative.exercise_date: The option will become exercisable as to 2.778% of the original number of shares at the end of each successive one-month period following the vesting commencement date, August 1, 2016, until the option is fully vested on the third anniversary of the vesting commencement date.

SEC source: 0000856982-18-000053 · wf-form4_152875505297666.xml · derivative · entry 2

Gunderson Thomas James · CIK 0001708144 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2025-06-07

F2 · derivative.exercise_date: Becomes exercisable in equal annual installments of 20% commencing 06/07/2019.